Merck at BPI West 2027
Mar 16–18, 2027 San Diego, CA ~800 attendees Website
Merck takes part in 5 sessions at BPI West 2027 in San Diego. Its sessions centre on analytics and computer modelling, applied to clearing downstream purification bottlenecks. It also covers how mass spectrometry and molecular modelling revealed off-target tyrosine conjugation in an antibody-drug conjugate, while its cell line development sessions have topics still to be announced.
| Organization | BPI West 2027 Attendance |
|---|---|
Merck Rahway, New Jersey | |
Global pharmaceutical company (Merck & Co., known as MSD outside the US and Canada) developing and manufacturing medicines, vaccines and biologics. | Talk Wed Mar 17 10:00am–10:30am Overcoming Downstream Purification Bottlenecks using Advanced Analytics and In-silico Approaches How salt-tolerant capture steps, tracking problem proteins left from the producing cells and computer modeling help clear purification bottlenecks. Talk Wed Mar 17 11:45am–12:15pm Panel Wed Mar 17 4:45pm–5:15pm Cell Line Development & Engineering: title to be announced Which tools and workflow changes, from automation to better data and predictive models, are likely to reshape cell line development within five years. Talk Thu Mar 18 9:30am–10:00am Talk Thu Mar 18 11:45am–12:15pm Integrated Mass Spectrometry and Molecular Modeling Reveal Off-Target Tyrosine Conjugation in a Sulfonylpyrimidine-Based ADC How mass spectrometry and modeling traced an antibody–drug conjugate impurity, which rose about 5-fold at higher pH, to drug wrongly attaching to tyrosine. |
Instantly find 20 buyers from Merck
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by BioProcess International or its organizers. Submit a correction